Elicio Therapeutics (ELTX) Cash & Equivalents (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Cash & Equivalents data on file, last reported at $14.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 18.81% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (down 18.81% YoY) and the FY2025 annual result came in at $18.6 million, up 5.36% from the prior year.
• Cash & Equivalents declined to $14.9 million in Q1 2026, from $18.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $73.0 million in Q1 2022 to a low of $598000.0 in Q2 2022.
• A 5-year average of $17.2 million and a median of $14.9 million in 2026 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 99.49% — and 2023, when it soared 3525.75%.
• Tracing ELTX's Cash & Equivalents over 5 years: stood at $6.2 million in 2022, then soared by 109.45% to $12.9 million in 2023, then soared by 36.64% to $17.6 million in 2024, then advanced by 5.36% to $18.6 million in 2025, then slipped by 19.73% to $14.9 million in 2026.
• The last three Cash & Equivalents figures came in at $14.9 million (Q1 2026), $18.6 million (Q4 2025), and $20.6 million (Q3 2025), per Business Quant data.